We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The market for biomaterials is expanding as medical device manufacturers seek to integrate lighter, safer, sturdier materials into implantable products such as drug-eluting stents, an analyst said in a recent briefing.
GS1 EPCglobal, a nonprofit that works on promoting worldwide adoption of electronic product codes (EPCs), said it has ratified the Electronic Pedigree Document standard. This can be used to give drugs epedigrees.
The FDA wants to create an electronic network to gather and share medical product safety information with healthcare professionals and patients, the agency announced.
Optimata, an Israeli company, has signed an expanded collaboration agreement with Eli Lilly, under which Optimata will use computer simulations to help the pharma giant narrow down the possible conditions under which investigational new drugs are to be tested, saving effort at both the preclinical and clinical testing stages.
As IT becomes integral in medical device design, clinical and IT specialists need better communication during the earliest stages of device development, experts said at a recent audioconference hosted by healthcare research group ECRI.
The FDA is rejecting the notion that it should allow unapproved prescription drugs that meet category-wide safety and efficacy standards to be approved for marketing, arguing that the risks are too great and that the approach is too expensive and time-consuming.
The FDA wants to impose new electronic reporting requirements on biological product manufacturers to assist in potential product recalls, the agency said.
GS1 EPCglobal, a nonprofit that works on promoting worldwide adoption of electronic product codes (EPCs), said it has ratified the Electronic Pedigree Document standard. This can be used to give drugs epedigrees.
The FDA wants to create an electronic network to gather and share medical product safety information with healthcare professionals and patients, the agency announced.
Optimata, an Israeli company, has signed an expanded collaboration agreement with Eli Lilly, under which Optimata will use computer simulations to help the pharma giant narrow down the possible conditions under which investigational new drugs are to be tested, saving effort at both the preclinical and clinical testing stages.